Category: Rehab & Therapeutics

Patients with Untreated Hearing Loss May Incur Higher Total Health Care Costs

Compared to the patients without hearing loss, patients with the condition generated nearly 26% more in total health care costs within two years, a gap that widened to 46% by 10 years, amounting to $22,434 per individual ($20,403 incurred by the health plan, $2,030 by the individual in out-of-pocket costs).

Read More

Otonomy Announces Plan to Focus on Development of Drug for Ménière’s Disease

Otonomy intends to complete the clinical development to support registration of OTIVIDEX in the United States for patients with Ménière’s disease, and will advance multiple programs for the prevention and treatment of sensorineural hearing loss, and the treatment of tinnitus.

Read More

Treatment of Ménière’s Disease and Vertigo with Intranasal Betahistine to be Developed by Auris Medical

Auris Medical will develop betahistine dihydrochloride in a spray formulation for the intranasal treatment of Ménière’s disease and vestibular vertigo. The company also announced last week that it has resumed patient enrollment in the TACTT3 Phase 3 trial of Keyzilen® (AM-101) for acute and post-acute inner ear tinnitus.

Read More

University Installs Balance Mobility Trainer to Reduce Risk of Falls

New balance mobility equipment on St. Augustine University’s Texas campus is the first to be easily accessible to patients in the Austin community who have balance problems from a stroke, spinal cord injury, spina bifida, multiple sclerosis, or traumatic brain injury, as well as geriatric patients who are at risk for injury from falls.

Read More